Concepts (197)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 6 | 2023 | 72 | 3.190 |
Why?
|
| Osteoporosis | 4 | 2022 | 15 | 2.450 |
Why?
|
| Familial Hypophosphatemic Rickets | 3 | 2023 | 3 | 2.220 |
Why?
|
| Bone Density | 12 | 2023 | 47 | 2.080 |
Why?
|
| Animals | 25 | 2023 | 734 | 1.920 |
Why?
|
| Bone and Bones | 8 | 2023 | 48 | 1.750 |
Why?
|
| Biomarkers | 7 | 2022 | 51 | 1.590 |
Why?
|
| Female | 15 | 2023 | 1137 | 1.560 |
Why?
|
| Humans | 21 | 2023 | 2210 | 1.370 |
Why?
|
| Male | 18 | 2023 | 1214 | 1.250 |
Why?
|
| Osteolysis | 4 | 2019 | 15 | 1.180 |
Why?
|
| Bone Remodeling | 4 | 2021 | 28 | 1.170 |
Why?
|
| Osteocalcin | 5 | 2022 | 10 | 1.140 |
Why?
|
| Calcium, Dietary | 2 | 2018 | 5 | 1.130 |
Why?
|
| Implants, Experimental | 3 | 2021 | 11 | 1.030 |
Why?
|
| Bone Matrix | 2 | 2017 | 9 | 0.970 |
Why?
|
| X-Ray Microtomography | 8 | 2023 | 37 | 0.950 |
Why?
|
| Anti-HIV Agents | 2 | 2023 | 10 | 0.940 |
Why?
|
| Mice | 9 | 2023 | 208 | 0.930 |
Why?
|
| Fractures, Bone | 2 | 2022 | 13 | 0.860 |
Why?
|
| Osseointegration | 3 | 2021 | 23 | 0.860 |
Why?
|
| Tooth | 1 | 2023 | 1 | 0.850 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2023 | 3 | 0.810 |
Why?
|
| Bone Development | 1 | 2023 | 15 | 0.800 |
Why?
|
| Alzheimer Disease | 2 | 2023 | 91 | 0.770 |
Why?
|
| Lactation | 2 | 2018 | 4 | 0.730 |
Why?
|
| HIV Seropositivity | 1 | 2021 | 17 | 0.710 |
Why?
|
| Bone-Implant Interface | 1 | 2020 | 3 | 0.690 |
Why?
|
| Prosthesis Retention | 1 | 2020 | 3 | 0.690 |
Why?
|
| Joint Prosthesis | 1 | 2020 | 10 | 0.680 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2021 | 94 | 0.650 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2018 | 11 | 0.630 |
Why?
|
| Rats | 10 | 2021 | 156 | 0.630 |
Why?
|
| Bone Regeneration | 5 | 2021 | 33 | 0.620 |
Why?
|
| Parathyroid Hormone | 2 | 2021 | 6 | 0.620 |
Why?
|
| Titanium | 2 | 2021 | 31 | 0.610 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2018 | 3 | 0.600 |
Why?
|
| Weaning | 1 | 2018 | 2 | 0.600 |
Why?
|
| Minerals | 1 | 2018 | 4 | 0.600 |
Why?
|
| Glycoproteins | 2 | 2018 | 13 | 0.590 |
Why?
|
| Cognitive Dysfunction | 1 | 2018 | 54 | 0.570 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2018 | 23 | 0.570 |
Why?
|
| Phosphates | 3 | 2021 | 6 | 0.500 |
Why?
|
| Osteogenesis | 3 | 2021 | 35 | 0.470 |
Why?
|
| Antibodies | 1 | 2014 | 10 | 0.440 |
Why?
|
| Osteoporotic Fractures | 1 | 2014 | 3 | 0.440 |
Why?
|
| Calcitonin | 1 | 2014 | 4 | 0.440 |
Why?
|
| Bone Density Conservation Agents | 1 | 2014 | 4 | 0.440 |
Why?
|
| Fracture Fixation | 1 | 2014 | 4 | 0.430 |
Why?
|
| Diphosphonates | 1 | 2014 | 5 | 0.430 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 26 | 0.430 |
Why?
|
| Absorptiometry, Photon | 3 | 2023 | 11 | 0.420 |
Why?
|
| Graft vs Host Disease | 2 | 2022 | 13 | 0.370 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2022 | 25 | 0.360 |
Why?
|
| Fibroblast Growth Factors | 2 | 2021 | 2 | 0.350 |
Why?
|
| PHEX Phosphate Regulating Neutral Endopeptidase | 2 | 2021 | 2 | 0.350 |
Why?
|
| Wnt Signaling Pathway | 2 | 2021 | 7 | 0.330 |
Why?
|
| Bone Diseases, Metabolic | 2 | 2023 | 6 | 0.320 |
Why?
|
| Femur | 4 | 2021 | 77 | 0.290 |
Why?
|
| Prosthesis Failure | 2 | 2020 | 25 | 0.280 |
Why?
|
| Middle Aged | 2 | 2021 | 608 | 0.270 |
Why?
|
| Polyethyleneimine | 3 | 2015 | 6 | 0.260 |
Why?
|
| Aged | 2 | 2018 | 490 | 0.260 |
Why?
|
| Calcium | 2 | 2018 | 189 | 0.250 |
Why?
|
| Skull | 2 | 2015 | 6 | 0.230 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 69 | 0.230 |
Why?
|
| Adult | 3 | 2022 | 681 | 0.220 |
Why?
|
| Tissue Scaffolds | 2 | 2014 | 7 | 0.220 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2021 | 6 | 0.210 |
Why?
|
| Periodontal Ligament | 1 | 2023 | 1 | 0.210 |
Why?
|
| Prostheses and Implants | 2 | 2014 | 37 | 0.210 |
Why?
|
| Disease Models, Animal | 3 | 2022 | 98 | 0.210 |
Why?
|
| Biomechanical Phenomena | 2 | 2020 | 69 | 0.210 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2023 | 2 | 0.200 |
Why?
|
| Mice, Transgenic | 1 | 2023 | 24 | 0.200 |
Why?
|
| HIV-1 | 1 | 2023 | 40 | 0.200 |
Why?
|
| Osteocytes | 2 | 2019 | 5 | 0.200 |
Why?
|
| Anti-Retroviral Agents | 1 | 2022 | 3 | 0.190 |
Why?
|
| Cartilage | 1 | 2022 | 12 | 0.190 |
Why?
|
| Neuropsychological Tests | 1 | 2022 | 112 | 0.190 |
Why?
|
| Cognition | 1 | 2022 | 79 | 0.190 |
Why?
|
| Hypogonadism | 1 | 2021 | 1 | 0.190 |
Why?
|
| Infertility | 1 | 2021 | 1 | 0.190 |
Why?
|
| Testicular Neoplasms | 1 | 2021 | 6 | 0.190 |
Why?
|
| Emtricitabine | 1 | 2021 | 1 | 0.180 |
Why?
|
| Femur Neck | 1 | 2021 | 6 | 0.180 |
Why?
|
| Rats, Zucker | 1 | 2021 | 2 | 0.180 |
Why?
|
| Ovariectomy | 1 | 2021 | 6 | 0.180 |
Why?
|
| Collagen Type I | 1 | 2021 | 3 | 0.180 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2021 | 10 | 0.180 |
Why?
|
| Viral Load | 1 | 2021 | 10 | 0.180 |
Why?
|
| Adipose Tissue | 1 | 2021 | 6 | 0.180 |
Why?
|
| Azepines | 1 | 2021 | 1 | 0.180 |
Why?
|
| Chondrosarcoma | 1 | 2021 | 1 | 0.180 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2021 | 1 | 0.180 |
Why?
|
| Triazoles | 1 | 2021 | 3 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2021 | 6 | 0.180 |
Why?
|
| Transcription Factors | 1 | 2021 | 33 | 0.170 |
Why?
|
| Bone Neoplasms | 1 | 2021 | 10 | 0.170 |
Why?
|
| Plasmids | 3 | 2015 | 10 | 0.170 |
Why?
|
| Arthroplasty, Replacement | 1 | 2020 | 9 | 0.170 |
Why?
|
| Body Weight | 1 | 2019 | 13 | 0.160 |
Why?
|
| Independent Living | 1 | 2018 | 11 | 0.150 |
Why?
|
| Porosity | 1 | 2018 | 14 | 0.150 |
Why?
|
| Memory, Short-Term | 1 | 2018 | 14 | 0.150 |
Why?
|
| Comorbidity | 1 | 2018 | 29 | 0.150 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 13 | 0.150 |
Why?
|
| Prognosis | 1 | 2018 | 38 | 0.150 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 40 | 0.150 |
Why?
|
| Double-Blind Method | 1 | 2018 | 37 | 0.150 |
Why?
|
| Prevalence | 1 | 2018 | 39 | 0.150 |
Why?
|
| Pregnancy | 1 | 2018 | 44 | 0.150 |
Why?
|
| Risk Assessment | 1 | 2018 | 38 | 0.150 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 62 | 0.150 |
Why?
|
| Syndactyly | 1 | 2018 | 1 | 0.150 |
Why?
|
| Hyperostosis | 1 | 2018 | 1 | 0.150 |
Why?
|
| Anabolic Agents | 1 | 2018 | 2 | 0.150 |
Why?
|
| Radiography | 1 | 2018 | 61 | 0.140 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 235 | 0.140 |
Why?
|
| Gene Transfer Techniques | 2 | 2015 | 9 | 0.140 |
Why?
|
| Cortical Bone | 1 | 2017 | 2 | 0.130 |
Why?
|
| RNA | 1 | 2015 | 3 | 0.120 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2015 | 10 | 0.120 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2015 | 6 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 9 | 0.120 |
Why?
|
| Copper | 1 | 2014 | 6 | 0.110 |
Why?
|
| Chitosan | 1 | 2014 | 3 | 0.110 |
Why?
|
| Microvessels | 1 | 2014 | 3 | 0.110 |
Why?
|
| Corpus Striatum | 1 | 2014 | 10 | 0.110 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2014 | 5 | 0.110 |
Why?
|
| Methamphetamine | 1 | 2014 | 5 | 0.110 |
Why?
|
| Fracture Healing | 1 | 2014 | 9 | 0.110 |
Why?
|
| Diaphyses | 1 | 2014 | 3 | 0.110 |
Why?
|
| Organ Specificity | 1 | 2014 | 3 | 0.110 |
Why?
|
| Macaca fascicularis | 1 | 2014 | 3 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 12 | 0.110 |
Why?
|
| Models, Animal | 1 | 2014 | 25 | 0.110 |
Why?
|
| Thiophenes | 1 | 2014 | 3 | 0.110 |
Why?
|
| Orthopedic Fixation Devices | 1 | 2014 | 4 | 0.110 |
Why?
|
| Humerus | 1 | 2014 | 11 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 19 | 0.110 |
Why?
|
| Bone Resorption | 1 | 2014 | 15 | 0.110 |
Why?
|
| Tibia | 1 | 2014 | 23 | 0.110 |
Why?
|
| Lumbar Vertebrae | 1 | 2014 | 27 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 69 | 0.110 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2013 | 2 | 0.110 |
Why?
|
| Bone Marrow | 2 | 2022 | 13 | 0.090 |
Why?
|
| Quality of Life | 2 | 2022 | 29 | 0.090 |
Why?
|
| DNA | 3 | 2015 | 21 | 0.090 |
Why?
|
| Rats, Inbred F344 | 3 | 2015 | 7 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 2 | 2021 | 12 | 0.070 |
Why?
|
| Calcification, Physiologic | 2 | 2019 | 10 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2021 | 19 | 0.070 |
Why?
|
| Cell Survival | 2 | 2015 | 14 | 0.060 |
Why?
|
| Genetic Therapy | 2 | 2015 | 16 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 88 | 0.050 |
Why?
|
| Lamivudine | 1 | 2023 | 3 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 9 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 2 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2022 | 3 | 0.050 |
Why?
|
| Disease Progression | 1 | 2022 | 46 | 0.050 |
Why?
|
| Immunoassay | 1 | 2021 | 3 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2021 | 3 | 0.040 |
Why?
|
| Cellular Senescence | 1 | 2021 | 3 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 4 | 0.040 |
Why?
|
| Proteins | 1 | 2021 | 6 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 16 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 3 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2019 | 6 | 0.040 |
Why?
|
| Surface Properties | 1 | 2019 | 18 | 0.040 |
Why?
|
| Polyethylene | 1 | 2019 | 6 | 0.040 |
Why?
|
| Motor Activity | 1 | 2019 | 21 | 0.040 |
Why?
|
| Loss of Function Mutation | 1 | 2018 | 1 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2018 | 10 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2018 | 6 | 0.040 |
Why?
|
| Spine | 1 | 2018 | 4 | 0.040 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2018 | 8 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2018 | 6 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2017 | 18 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2018 | 232 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 2015 | 7 | 0.030 |
Why?
|
| Craniocerebral Trauma | 1 | 2015 | 3 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2015 | 9 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2015 | 17 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 29 | 0.030 |
Why?
|
| Receptors, Endothelin | 1 | 2014 | 3 | 0.030 |
Why?
|
| Self Administration | 1 | 2014 | 4 | 0.030 |
Why?
|
| Vasoconstriction | 1 | 2014 | 3 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 3 | 0.030 |
Why?
|
| Hypoxia | 1 | 2014 | 4 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2014 | 5 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2014 | 10 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2013 | 9 | 0.030 |
Why?
|
| Transfection | 1 | 2013 | 19 | 0.030 |
Why?
|
| Collagen | 1 | 2013 | 21 | 0.030 |
Why?
|
| Gene Expression | 1 | 2013 | 27 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 26 | 0.030 |
Why?
|